Technology evaluation: HYB-2055, Hybridon.
Hybridon is developing immunomodulatory oligonucleotides. including injectable HYB-2055 (IMOxine) which acts as an agonist of toll-like receptor 9, for the potential treatment of cancer. HYB-2055 is currently undergoing phase II clinical trials. The immunomodulatory oligonucleotides are also being investigated for the potential treatment of infectious diseases and immune disorders.
Switaj
Tomasz
T
Center of Oncology--Institute Soft Tissue/Bone Sarcoma and Melanoma Department, Roentgena 5, Warsaw 02-781, Poland. tswitaj@ib.amwaw.edu.pl
Lasek
Witold
W
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003141:Communicable Diseases / Q000188:drug therapy; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy; D007155:Immunologic Factors / Q000627:therapeutic use*; D007267:Injections; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D009841:Oligonucleotides / Q000009:adverse effects / Q000627:therapeutic use*
C506514:HYB-2055; D007155:Immunologic Factors; D009841:Oligonucleotides